Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Adnan M. Nagrial; Venessa T. Chin; Katrin M. Sjoquist; Marina Pajic; Lisa G. Horvath; Andrew V. Biankin; Desmond Yip

doi:10.1016/j.critrevonc.2015.07.007

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Adnan M. Nagrial^*, Venessa T. Chin, Katrin M. Sjoquist, Marina Pajic, Lisa G. Horvath, Andrew V. Biankin, Desmond Yip

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

Abstract

There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.

Original language	English
Pages (from-to)	483-497
Number of pages	15
Journal	Critical Reviews in Oncology/Hematology
Volume	96
Issue number	3
Early online date	26 Jul 2015
DOIs	https://doi.org/10.1016/j.critrevonc.2015.07.007
Publication status	Published - Dec 2015

Access to Document

10.1016/j.critrevonc.2015.07.007

Cite this

@article{2fde2d4fd13148cd83494e27ca6ee8a3,

title = "Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials",

abstract = "There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.",

keywords = "Chemotherapy, Pancreatic cancer, Second-line, Systematic review, Trials",

author = "Nagrial, \{Adnan M.\} and Chin, \{Venessa T.\} and Sjoquist, \{Katrin M.\} and Marina Pajic and Horvath, \{Lisa G.\} and Biankin, \{Andrew V.\} and Desmond Yip",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ireland Ltd.",

year = "2015",

month = dec,

doi = "10.1016/j.critrevonc.2015.07.007",

language = "English",

volume = "96",

pages = "483--497",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

AU - Nagrial, Adnan M.

AU - Chin, Venessa T.

AU - Sjoquist, Katrin M.

AU - Pajic, Marina

AU - Horvath, Lisa G.

AU - Biankin, Andrew V.

AU - Yip, Desmond

PY - 2015/12

Y1 - 2015/12

N2 - There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.

AB - There remains uncertainty regarding the optimal second-line chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). The current recommendation of 5-fluorouracil and oxaliplatin may not be relevant in current practice, as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) has become a more popular first line therapy in fit patients. The majority of studies in this setting are single-arm Phase II trials with significant heterogeneity of patient populations, treatments and outcomes. In this review, we sought to systematically review and synthesise all prospective data available for the second-line treatment of advanced PDAC.

KW - Chemotherapy

KW - Pancreatic cancer

KW - Second-line

KW - Systematic review

KW - Trials

UR - https://www.scopus.com/pages/publications/84959121182

U2 - 10.1016/j.critrevonc.2015.07.007

DO - 10.1016/j.critrevonc.2015.07.007

M3 - Article

C2 - 26481952

SN - 1040-8428

VL - 96

SP - 483

EP - 497

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 3

ER -

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

Abstract

Access to Document

Other files and links

Fingerprint

Cite this